Targets › RLN2
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Dec 2026.
Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals. May be involved in remodeling of connective tissues during pregnancy, promoting growth of pubic ligaments and ripening of the cervix. (UniProt, P04090)
Open in Phaseline: the race on RLN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Relaxin RLN2-encoded endogenous peptide hormone that binds to G protein-coupled receptor RXFP1 | RLN2, RXFP1 | Phase 2 | Cardiovascular Diseases | Dec 2026 |
Cardiovascular Diseases (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.